Phaseline

Companies › Xiamen Amoytop Biotech

Xiamen Amoytop Biotech: clinical trials, targets and expected readouts

3 active drug programs in 8 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 1, 1 Phase 4; Infectious disease, Metabolic and endocrine, Other, Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Inpegsomatropin Injection
Pegylated recombinant human growth hormone (long-acting GH analog)
GH1Phase 3Small for Gestational Age; Turner Syndrome; Idiopathic Short Stature; Adult Growth Hormone DeficiencyDec 2027
Peginterferon Alfa-2B
Interferon alpha/beta receptor agonist
IFNAR1, IFNAR2Phase 2Essential Thrombocythemia; Hepatitis B, Chronic; Malignant MelanomaSep 2027
ACT201 Injection–Phase 1Chronic Hepaititis BMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05182463Peginterferon Alfa-2BPhase 4Hepatitis B, ChronicInfectious diseaseDec 2026
NCT07741461ACT201 InjectionPhase 1Chronic Hepaititis BInfectious diseaseMar 2027
NCT06552429Peginterferon Alfa-2BPhase 2Essential ThrombocythemiaOncologySep 2027
NCT07551804Inpegsomatropin InjectionPhase 2Adult Growth Hormone DeficiencyMetabolic and endocrineDec 2027
NCT07309562Inpegsomatropin InjectionPhase 3Small for Gestational AgeOtherMar 2028
NCT07614152Inpegsomatropin InjectionPhase 3Turner SyndromeOtherMar 2028
NCT06927310Inpegsomatropin InjectionPhase 3Idiopathic Short StatureMetabolic and endocrineJun 2028
NCT00539591Peginterferon Alfa-2BPhase 2Malignant MelanomaOncologyMay 2031

Targets

GH1 (1) IFNAR1 (1) IFNAR2 (1)

Companies with the same targets

Diakonos Oncology PharmaEssentia BriaCell Therapeutics Brii Biosciences Biogen Kexing Biopharm Changchun GeneScience Pharmaceutical Intervene Immune AstraZeneca Genrix (Shanghai) Biopharmaceutical

Companies built like this

SK Bioscience Immorna Biotherapeutics Kexing Biopharm GC Biopharma Huahui Health

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.